儿童感染SARS-CoV-2后6个月和12个月的COVID-19后状况
该多中心前瞻性队列研究纳入2020年8月至2022年2月在加拿大14个三级儿童急诊科检测SARS-CoV-2的18岁以下儿童,随访90天、6个月和12个月。6个月时,SARS-CoV-2阳性儿童中PCC比例为0.52%(6/1152),阴性儿童为0.10%(4/3995),绝对风险差0.42%(95%CI 0.02%至0.94%);12个月时阳性儿童PCC比例为0.67%(8/1192),阴性儿童为0.16%(7/4371),绝对风险差0.51%(95%CI 0.06至1.08)。12个月时PedsQL通用核心量表评分在阳性与阴性儿童间无显著差异(98.4 vs 98.8,差值-0.3,95%CI -1.5至0.8,P=0.56)。感染后长期症状虽有所增加,但真正符合PCC定义的儿童极少,总体生活质量与未感染儿童无差异。
要点
- 6个月随访时,SARS-CoV-2阳性儿童PCC比例为0.52%(6/1152),阴性儿童为0.10%(4/3995),绝对风险差0.42%(95%CI 0.02%至0.94%)。
- 12个月随访时,阳性儿童PCC比例为0.67%(8/1192),阴性儿童为0.16%(7/4371),绝对风险差0.51%(95%CI 0.06至1.08)。
- 12个月时PedsQL通用核心量表评分阳性组98.4(90.0-100) vs 阴性组98.8(91.7-100),差值-0.3(95%CI -1.5至0.8,P=0.56),无显著差异。
- 12个月时符合PCC的8例阳性儿童中,呼吸系统症状7/8(88%)、全身症状3/8(38%)、神经系统症状1/8(13%)。
- 在儿童急诊检测人群中,SARS-CoV-2感染后发展为PCC的比例很低,总体生活质量与检测阴性儿童无差异。
适用人群与场景
- 2020年8月至2022年2月在加拿大14个三级儿童急诊科(Pediatric Emergency Research Canada网络成员)检测SARS-CoV-2的18岁以下儿童。
- 暴露定义为索引急诊就诊时或就诊后14天内SARS-CoV-2感染阳性。
- 6个月分析纳入5147名儿童(阳性1152例,阴性3995例),12个月分析纳入5563名儿童(阳性1192例,阴性4371例),均为有足够主要结局数据以进行PCC分类者。
- 中位年龄2.0岁(IQR 0.9-5.0),男性2956/5563(53.1%)。
诊断标准与关键阈值
- PCC定义:任何在感染后3个月内出现、随访时仍持续并影响日常功能的症状。
研究设计与关键结果
- 多中心前瞻性队列研究,纳入14个加拿大三级儿童急诊科检测SARS-CoV-2的18岁以下儿童,随访90天、6个月和12个月。
- 6个月时,阳性组PCC 6/1152(0.52%),阴性组4/3995(0.10%),绝对风险差0.42%(95%CI 0.02%至0.94%)。
- 12个月时,阳性组PCC 8/1192(0.67%),阴性组7/4371(0.16%),绝对风险差0.51%(95%CI 0.06至1.08)。
- 12个月时PedsQL通用核心量表评分:阳性组中位98.4(IQR 90.0-100),阴性组98.8(IQR 91.7-100),差值-0.3(95%CI -1.5至0.8,P=0.56)。
- 12个月时8例阳性且符合PCC的儿童中,呼吸系统症状7/8(88%)、全身症状3/8(38%)、神经系统症状1/8(13%)。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
对床旁实践的改变
- 在儿童急诊检测人群中,SARS-CoV-2感染后6个月和12个月符合PCC定义的比例很低(0.52%和0.67%),总体生活质量与检测阴性儿童无差异。
- 感染后长期症状虽有所报告,但真正符合PCC定义并影响日常功能者极少,临床评估时应结合功能影响综合判断。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: There is a need to understand the long-term outcomes among children infected with SARS-CoV-2.
OBJECTIVE: To quantify the prevalence of post-COVID-19 condition (PCC) among children tested for SARS-CoV-2 infection in pediatric emergency departments (EDs).
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, prospective cohort study at 14 Canadian tertiary pediatric EDs that are members of the Pediatric Emergency Research Canada network with 90-day, 6-month, and 12-month follow-up. Participants were children younger than 18 years who were tested for SARS-CoV-2 infection between August 2020 and February 2022. Data were analyzed from May to November 2023.
EXPOSURE: The presence of SARS-CoV-2 infection at or within 14 days of the index ED visit.
MAIN OUTCOMES AND MEASURES: Presence of symptoms and QoL reductions that meet the PCC definition. This includes any symptom with onset within 3 months of infection that is ongoing at the time of follow-up and affects everyday functioning. The outcome was quantified at 6 and 12 months following the index ED visit.
RESULTS: Among the 5147 children at 6 months (1152 with SARS-CoV-2 positive tests and 3995 with negative tests) and 5563 children at 12 months (1192 with SARS-CoV-2 positive tests and 4371 with negative tests) who had sufficient data regarding the primary outcome to enable PCC classification, the median (IQR) age was 2.0 (0.9-5.0) years, and 2956 of 5563 (53.1%) were male. At 6-month follow-up, symptoms and QoL changes consistent with the PCC definition were present in 6 of 1152 children with positive SARS-CoV-2 tests (0.52%) and 4 of 3995 children with negative SARS-CoV-2 tests (0.10%; absolute risk difference, 0.42%; 95% CI, 0.02% to 0.94%). The PCC definition was met at 12 months by 8 of 1192 children with positive SARS-CoV-2 tests (0.67%) and 7 of 4371 children with negative SARS-CoV-2 tests (0.16%; absolute risk difference, 0.51%; 95% CI, 0.06 to 1.08%). At 12 months, the median (IQR) PedsQL Generic Core Scale scores were 98.4 (90.0-100) among children with positive SARS-CoV-2 tests and 98.8 (91.7-100) among children with negative SARS-CoV-2 tests (difference, -0.3; 95% CI, -1.5 to 0.8; P = .56). Among the 8 children with SARS-CoV-2 positive tests and PCC at 12-month follow-up, children reported respiratory (7 of 8 patients [88%]), systemic (3 of 8 patients [38%]), and neurologic (1 of 8 patients [13%]) symptoms.
CONCLUSIONS AND RELEVANCE: In this cohort study of children tested for SARS-CoV-2 infection in Canadian pediatric EDs, although children infected with SARS-CoV-2 reported increased chronic symptoms, few of these children developed PCC, and overall QoL did not differ from children with negative SARS-CoV-2 tests.
参考来源
- Dun-Dery F, Xie J, Winston K, et al. Post-COVID-19 Condition in Children 6 and 12 Months After Infection. JAMA Netw Open. 2023. PMID: 38153737. doi:10.1001/jamanetworkopen.2023.49613
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。